IN2012DN02736A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN02736A IN2012DN02736A IN2736DEN2012A IN2012DN02736A IN 2012DN02736 A IN2012DN02736 A IN 2012DN02736A IN 2736DEN2012 A IN2736DEN2012 A IN 2736DEN2012A IN 2012DN02736 A IN2012DN02736 A IN 2012DN02736A
- Authority
- IN
- India
- Prior art keywords
- compounds
- toll
- vaccine
- adjuvants
- receptors
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000002689 Toll-like receptor Human genes 0.000 abstract 1
- 108020000411 Toll-like receptor Proteins 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- AIDS & HIV (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23921709P | 2009-09-02 | 2009-09-02 | |
| PCT/US2010/047587 WO2011049677A1 (fr) | 2009-09-02 | 2010-09-01 | Composés et compositions utilisés en tant que modulateurs de l'activité tlr |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN02736A true IN2012DN02736A (fr) | 2015-09-11 |
Family
ID=43625759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2736DEN2012 IN2012DN02736A (fr) | 2009-09-02 | 2010-09-01 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US9045470B2 (fr) |
| EP (1) | EP2473508B1 (fr) |
| JP (1) | JP5525614B2 (fr) |
| CN (1) | CN102712636B (fr) |
| AR (1) | AR078153A1 (fr) |
| AU (1) | AU2010308524B2 (fr) |
| BR (1) | BR112012004696B8 (fr) |
| CA (1) | CA2772657C (fr) |
| CL (1) | CL2012000535A1 (fr) |
| CY (1) | CY1119618T1 (fr) |
| DK (1) | DK2473508T3 (fr) |
| EA (1) | EA020962B1 (fr) |
| ES (1) | ES2627669T3 (fr) |
| HR (1) | HRP20170707T1 (fr) |
| HU (1) | HUE032323T2 (fr) |
| IN (1) | IN2012DN02736A (fr) |
| JO (1) | JO3257B1 (fr) |
| LT (1) | LT2473508T (fr) |
| MX (1) | MX2012002654A (fr) |
| PE (1) | PE20121156A1 (fr) |
| PL (1) | PL2473508T3 (fr) |
| PT (1) | PT2473508T (fr) |
| SI (1) | SI2473508T1 (fr) |
| TW (1) | TWI445708B (fr) |
| UY (1) | UY32874A (fr) |
| WO (1) | WO2011049677A1 (fr) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012125942A1 (fr) * | 2011-03-16 | 2012-09-20 | University Of Medicine And Dentistry Of New Jersey | Polythérapie faisant intervenir la leucotoxine |
| US10149889B2 (en) | 2005-11-25 | 2018-12-11 | Rutgers, The State University Of New Jersey | Compositions for the treatment of cancer, and methods for testing and using the same |
| US8926990B2 (en) | 2009-10-13 | 2015-01-06 | Rutgers, The State University Of New Jersey | Treatment and diagnosis of inflammatory disorders and HIV |
| PT2364314E (pt) | 2008-12-09 | 2014-06-09 | Gilead Sciences Inc | Moduladores de recetores toll-like |
| DK2459216T3 (da) | 2009-09-02 | 2013-12-09 | Novartis Ag | Immunogene sammensætninger omfattende tlr-aktivitetsmodulatorer |
| SG10201501980SA (en) | 2009-12-15 | 2015-05-28 | Novartis Ag | Homogeneous suspension of immunopotentiating compounds and uses thereof |
| EP2402028A1 (fr) * | 2010-07-01 | 2012-01-04 | Sanofi Pasteur | Vaccins d'entérovirus pour la prévention et le traitement du diabète de type 1 (II) |
| ES2770335T3 (es) | 2010-07-06 | 2020-07-01 | Glaxosmithkline Biologicals Sa | Administración de ARN para desencadenar múltiples vías inmunológicas |
| BR112013000244A2 (pt) | 2010-07-06 | 2016-05-17 | Novartis Ag | lipossomas com lipídeos apresentando pka vantajoso para administração de rna |
| EP2591114B1 (fr) | 2010-07-06 | 2016-06-08 | GlaxoSmithKline Biologicals SA | Immunisation de grands mammifères à l'aide de faibles doses d'arn |
| AU2011295935B2 (en) | 2010-08-31 | 2016-02-11 | Glaxosmithkline Biologicals S.A. | Pegylated liposomes for delivery of immunogen-encoding RNA |
| ES2458355T3 (es) | 2010-09-01 | 2014-05-05 | Novartis Ag | Adsorción de inmunopotenciadores sobre sales metálicas insolubles |
| KR102266691B1 (ko) | 2010-10-11 | 2021-06-23 | 노파르티스 아게 | 항원 전달 플랫폼 |
| BR112013022397A2 (pt) | 2011-03-02 | 2017-09-26 | Derek OHagan | vacinas combinadas com doses menores de antígeno e/ou adjuvante |
| US8900626B2 (en) * | 2011-06-20 | 2014-12-02 | Senju Usa, Inc. | Transdermal drug delivery system and method of using the same |
| JP2014522842A (ja) * | 2011-07-06 | 2014-09-08 | ノバルティス アーゲー | 免疫原性組み合わせ組成物およびその使用 |
| MX2014002363A (es) | 2011-09-01 | 2014-04-14 | Novartis Ag | Formulaciones de antigenos de staphylococcus aureus con adyuvante. |
| FI123955B (en) | 2011-11-25 | 2014-01-15 | Oncos Therapeutics Ltd | Oncolytic adenovirus |
| JP2015510872A (ja) * | 2012-03-07 | 2015-04-13 | ノバルティス アーゲー | Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ抗原の増強された製剤 |
| EP2822589A1 (fr) | 2012-03-07 | 2015-01-14 | Novartis AG | Formulations d'immunogènes du virus rabique, pourvues d'un adjuvant |
| SI2822947T1 (sl) * | 2012-03-07 | 2016-10-28 | Glaxosmithkline Biologicals S.A. | Argininske soli TLR7 agonista |
| JP6345603B2 (ja) * | 2012-03-08 | 2018-06-20 | ノバルティス アーゲー | 追加免疫ワクチンのアジュバント化された処方物 |
| EP2674170B1 (fr) | 2012-06-15 | 2014-11-19 | Invivogen | Nouvelles compositions d'agonistes TLR7 et/ou TLR8 conjugués à des lipides |
| EP2877492A1 (fr) | 2012-07-27 | 2015-06-03 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Utilisation du cd147 comme récepteur pour l'adhésion impliquant les pili des méningocoques à l'endothélium vasculaire |
| US20150202277A1 (en) * | 2012-08-31 | 2015-07-23 | Novartis Ag | Stabilised proteins for immunising against staphylococcus aureus |
| EP2732825B1 (fr) | 2012-11-19 | 2015-07-01 | Invivogen | Conjugués d'un agoniste de TLR7 et/ou TLR8 avec un agoniste de TLR2 |
| CN103845731B (zh) * | 2012-12-05 | 2015-12-02 | 复旦大学 | 抗st2/il-1r4抗体在制备防治瘙痒药物中的应用 |
| US20140193484A1 (en) * | 2013-01-10 | 2014-07-10 | Sylvie Carine Bertholet Girardin | Influenza virus immunogenic compositions and uses thereof |
| WO2014118305A1 (fr) | 2013-02-01 | 2014-08-07 | Novartis Ag | Administration intradermique de compositions immunologiques comprenant des agonistes des récepteurs de type toll |
| EP2769738B1 (fr) | 2013-02-22 | 2016-07-20 | Invivogen | Conjugués TLR7 et/ou TLR8 et agonistes polycationiques TLR2 |
| MX2015015428A (es) | 2013-05-10 | 2016-07-18 | Novartis Ag | Eliminacion de riesgo de narcolepsia en vacunas contra influenza. |
| CN104338129B (zh) * | 2013-07-26 | 2017-05-24 | 中国科学院上海巴斯德研究所 | 雷帕霉素作为疫苗佐剂的用途及制备方法 |
| NZ728072A (en) | 2014-07-11 | 2018-06-29 | Gilead Sciences Inc | Modulators of toll-like receptors for the treatment of hiv |
| CA2960436C (fr) | 2014-09-16 | 2021-01-05 | Gilead Sciences, Inc. | Formes solides d'un modulateur de recepteurs de type toll |
| EP3061826A1 (fr) * | 2015-02-27 | 2016-08-31 | Novartis AG | Réplicons du flavivirus |
| JP7046016B2 (ja) | 2016-06-30 | 2022-04-01 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Ｈｅｒｖ－ｅ反応性ｔ細胞受容体および使用方法 |
| WO2018047888A1 (fr) * | 2016-09-09 | 2018-03-15 | 武田薬品工業株式会社 | Composé cyclique |
| AR111760A1 (es) * | 2017-05-19 | 2019-08-14 | Novartis Ag | Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral |
| TW202003475A (zh) * | 2018-06-04 | 2020-01-16 | 美商亞博創新醫藥有限公司 | 含酸性基團之嘧啶化合物 |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| KR20210106437A (ko) | 2018-12-20 | 2021-08-30 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물 |
| BR112021015577A8 (pt) | 2019-02-08 | 2021-10-05 | Research & Business Found Sungkyunkwan Univ | Complexo-colesterol agonista do receptor toll-like 7/8, composição de nanopartícula, composição adjuvante, composição de vacina, composição para regular uma função imunológica, composição farmacêutica e uso do complexo |
| CA3123519A1 (fr) | 2019-02-15 | 2020-08-20 | Novartis Ag | Derives de 3-(1-oxoisoindoline-2-yl)piperidine-2,6-dione substitues et leurs utilisations |
| MX2021009763A (es) | 2019-02-15 | 2021-09-08 | Novartis Ag | Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos. |
| JP2023507190A (ja) | 2019-12-20 | 2023-02-21 | ノバルティス アーゲー | 増殖性疾患を治療するための抗ＴＧＦβ抗体及びチェックポイント阻害薬の使用 |
| WO2021126281A1 (fr) | 2019-12-20 | 2021-06-24 | Nammi Therapeutics, Inc. | Compositions liposomales formulées et/ou co-formulées contenant des promédicaments agonistes de récepteurs de type toll (« tlr ») utiles dans le traitement du cancer et méthodes associées |
| US20230100429A1 (en) | 2020-03-02 | 2023-03-30 | Progeneer Inc. | Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof |
| WO2021260528A1 (fr) | 2020-06-23 | 2021-12-30 | Novartis Ag | Schéma posologique comprenant des dérivés de 3-(1-oxoisoindoline-2-yl) pipéridine-2,6-dione |
| WO2022009157A1 (fr) | 2020-07-10 | 2022-01-13 | Novartis Ag | Combinaisons de lhc165 et de spartalizumab pour le traitement de tumeurs solides |
| WO2022029573A1 (fr) | 2020-08-03 | 2022-02-10 | Novartis Ag | Dérivés de 3-(1-oxoisoindolin-2-yl)pipéridine-2,6-dione substitués par hétéroaryle et leurs utilisations |
| JP2023536953A (ja) | 2020-08-04 | 2023-08-30 | プロジェニア インコーポレイテッド | 動力学的制御が可能なアジュバントを含むｍＲＮＡワクチン |
| US20230277525A1 (en) | 2020-08-04 | 2023-09-07 | Progeneer Inc | Conjugate of functional drug and toll-like receptor 7 or 8 agonist of which active site is temporarily inactivated and use thereof |
| JP2023536945A (ja) | 2020-08-04 | 2023-08-30 | プロジェニア インコーポレイテッド | 動力学的に作用するアジュバントアンサンブル |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
| WO2023109909A1 (fr) * | 2021-12-15 | 2023-06-22 | 上海翊石医药科技有限公司 | Composés hétérocycliques aromatiques, leur procédé de préparation et leurs utilisations |
| WO2023214325A1 (fr) | 2022-05-05 | 2023-11-09 | Novartis Ag | Dérivés de pyrazolopyrimidine et leurs utilisations en tant qu'inhibiteurs de tet2 |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2848965A1 (de) | 1978-11-11 | 1980-05-22 | Behringwerke Ag | Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine |
| US5389640A (en) * | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| IL117483A (en) | 1995-03-17 | 2008-03-20 | Bernard Brodeur | MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K. |
| US6180111B1 (en) | 1995-05-18 | 2001-01-30 | University Of Maryland | Vaccine delivery system |
| EP0907738A1 (fr) | 1996-04-02 | 1999-04-14 | Smithkline Beecham Corporation | Nouveaux composes |
| JP2000512487A (ja) | 1996-05-14 | 2000-09-26 | スミスクライン・ビーチャム・コーポレイション | 新規化合物 |
| EP1770164B1 (fr) | 1996-10-31 | 2010-09-01 | Human Genome Sciences, Inc. | Antigènes et vaccins pour streptococcus pneumoniae |
| GB9711964D0 (en) | 1997-06-09 | 1997-08-06 | Medical Res Council | Live attenuated vaccines |
| US6800744B1 (en) | 1997-07-02 | 2004-10-05 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics |
| DK0991761T3 (da) | 1997-08-21 | 2008-05-19 | Nederlanden Staat | Hidtil ukendte mutaner af gramnegative mucosale bakterier og anvendelse deraf i vacciner |
| JPH1180156A (ja) * | 1997-09-04 | 1999-03-26 | Hokuriku Seiyaku Co Ltd | １−（置換アリール）アルキル−１ｈ−イミダゾピリジン−４−アミン誘導体 |
| AU9363798A (en) | 1997-11-06 | 1999-05-31 | Chiron S.P.A. | Neisserial antigens |
| AU1537699A (en) | 1997-11-26 | 1999-06-15 | Bioresearch Ireland a division of Eolas - The Irish Science and Technology Agency | Extracellular matrix-binding proteins from (staphylococcus aureus) |
| EP2210945B1 (fr) | 1998-01-14 | 2013-06-26 | Novartis Vaccines and Diagnostics S.r.l. | Antigènes de Neisseria meningitidis |
| CA2328399A1 (fr) | 1998-04-23 | 1999-10-28 | University Of Alabama At Birmingham | Proteine de surface pneumococcique c(pspc), regions epitopes et selection de souches d'une telle proteine, et utilisations correspondantes |
| AU761780B2 (en) | 1998-05-01 | 2003-06-12 | Glaxosmithkline Biologicals Sa | Neisseria meningitidis antigens and compositions |
| GB9810193D0 (en) | 1998-05-12 | 1998-07-08 | Smithkline Beecham Biolog | Novel compounds |
| JP2002531055A (ja) | 1998-07-27 | 2002-09-24 | マイクロビアル テクニクス リミティッド | 肺炎連鎖球菌のタンパク質及び核酸分子 |
| CN1318103A (zh) | 1998-07-27 | 2001-10-17 | 微生物技术有限公司 | 肺炎链球菌的核酸和蛋白质 |
| JP4714342B2 (ja) | 1998-08-31 | 2011-06-29 | ザ プラヴアスト フエロウス アンド スカラース オブ ザ カレツヂ オブ ザ ハリー アンド アンデイヴアイデツド トリニテイ オブ クイーン エリザベス ニヤー ダブリン | コアグラーゼ陰性スタフィロコカス菌に由来のポリペプチド及びポリヌクレオチド |
| ES2322409T3 (es) | 1998-08-31 | 2009-06-19 | Inhibitex, Inc. | Vacunas multicomponentes contra staphylococcus aureus. |
| AU1202200A (en) | 1998-10-09 | 2000-05-01 | Chiron Corporation | Neisseria genomic sequences and methods of their use |
| GB9823978D0 (en) | 1998-11-02 | 1998-12-30 | Microbiological Res Authority | Multicomponent meningococcal vaccine |
| GB9828000D0 (en) | 1998-12-18 | 1999-02-10 | Chiron Spa | Antigens |
| AU776828B2 (en) | 1998-12-21 | 2004-09-23 | Medimmune, Llc | Streptococcus pneumoniae proteins and immunogenic fragments for vaccines |
| CN1198932C (zh) | 1999-03-26 | 2005-04-27 | 科特克斯(Om)有限公司 | 肺炎链球菌抗原 |
| ATE325620T1 (de) | 1999-06-10 | 2006-06-15 | Medimmune Inc | Streptococcus pneumoniae proteine und impfstoffe |
| EP1075841A1 (fr) | 1999-08-13 | 2001-02-14 | Erasmus Universiteit Rotterdam | Vaccins pneumococciques |
| WO2001034642A2 (fr) | 1999-11-12 | 2001-05-17 | University Of Iowa Research Foundation | Commande de la synthese de membrane de neisseria |
| DE60142772D1 (de) | 2000-01-17 | 2010-09-23 | Novartis Vaccines & Diagnostic | Membranvesikel (omv) impfstoff, der n. meningitidis serogruppe b membranproteine enthält |
| NZ521396A (en) | 2000-02-28 | 2004-06-25 | Chiron S | Fusion proteins comprising two or more Neisseria polypeptides |
| WO2001070955A2 (fr) | 2000-03-21 | 2001-09-27 | Elitra Pharmaceuticals, Inc. | Identification de genes esentiels dans des procaryotes |
| AU5577201A (en) | 2000-04-27 | 2001-11-07 | Med Immune Inc | Immunogenic pneumococcal protein and vaccine compositions thereof |
| NO20002828D0 (no) | 2000-06-02 | 2000-06-02 | Statens Inst For Folkehelse | Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav |
| US6495079B1 (en) | 2000-06-28 | 2002-12-17 | Prisma Fibers, Inc. | Process to prepare polymeric fibers with improved color and appearance |
| AU2001276619A1 (en) | 2000-07-03 | 2002-01-14 | Chiron S.P.A. | Immunisation against chlamydia pneumoniae |
| WO2002008426A2 (fr) | 2000-07-20 | 2002-01-31 | Hansa Medical Ab | Proteine |
| BRPI0112928B1 (pt) | 2000-07-27 | 2017-08-29 | Children's Hospital & Research Center At Oakland | A composition comprising preparations comprising outer membrane vesicles (OMV), microvesicles (MV) or both MVO and MV |
| GB0103170D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
| AU8743001A (en) | 2000-08-28 | 2002-03-13 | Aventis Pasteur | Moraxella polypeptides and corresponding dna fragments and uses thereof |
| GB0022742D0 (en) | 2000-09-15 | 2000-11-01 | Smithkline Beecham Biolog | Vaccine |
| EP1330473A2 (fr) | 2000-10-26 | 2003-07-30 | Imperial College Innovations Limited | Genes streptococciques |
| EP2277894A1 (fr) | 2000-10-27 | 2011-01-26 | Novartis Vaccines and Diagnostics S.r.l. | Acides nucléiques et protéines dérivés des groupes de streptocoques A et B |
| AT410798B (de) | 2001-01-26 | 2003-07-25 | Cistem Biotechnologies Gmbh | Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen |
| GB0103171D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
| GB0103424D0 (en) | 2001-02-12 | 2001-03-28 | Chiron Spa | Gonococcus proteins |
| AU2002306849A1 (en) | 2001-03-21 | 2002-10-08 | Elitra Pharmaceuticals, Inc. | Identification of essential genes in microorganisms |
| GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
| GB0108079D0 (en) | 2001-03-30 | 2001-05-23 | Microbial Technics Ltd | Protein |
| EP1399181B1 (fr) | 2001-05-18 | 2012-05-09 | The Government of the USA, as represented by the Secretary, Dept. of Health and Human Services, Centers for Disease Control and Prevention | Vaccins peptidiques contre les streptocoques du groupe a |
| MXPA03011701A (es) | 2001-06-15 | 2004-12-06 | Nhibitex Inc | Anticuerpos monoclonales y policlonales de reaccion que reconocen las proteinas de superficie a partir de estafilococos coagulasa-negativos y staphylococcus aureus. |
| GB0121591D0 (en) | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
| WO2003011899A2 (fr) | 2001-08-02 | 2003-02-13 | University Of Sheffield | Polypeptides antigeniques |
| CA2469620A1 (fr) | 2001-12-12 | 2003-06-19 | Chiron Srl. | Immunisation contre chlamydia trachomatis |
| GB0203403D0 (en) | 2002-02-13 | 2002-04-03 | Chiron Spa | Chlamydia cytotoxic-T cell epitopes |
| EP2275120A3 (fr) | 2002-04-02 | 2011-06-08 | Ben-Gurion University Of The Negev Research And Development Authority | Vaccins contre le streptococcus pneumoniae à base de protéine |
| GB0210128D0 (en) | 2002-05-02 | 2002-06-12 | Chiron Spa | Nucleic acids and proteins from streptococcus groups A & B |
| AU2003246411A1 (en) | 2002-06-11 | 2003-12-22 | Glaxo Group Limited | Immunogenic compositions |
| GB0213622D0 (en) | 2002-06-13 | 2002-07-24 | Glaxosmithkline Biolog Sa | Vaccine Corporation |
| PT1524993E (pt) | 2002-08-02 | 2013-06-12 | Glaxosmithkline Biolog Sa | Composições de vacina de neisseria compreendendo uma combinação de antigénios |
| GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
| EP1551357B1 (fr) | 2002-09-13 | 2014-07-16 | Novartis Vaccines and Diagnostics, Inc. | Vaccin contre les streptocoques du groupe b |
| EP2353608B1 (fr) | 2002-10-11 | 2019-12-18 | Novartis Vaccines and Diagnostics S.r.l. | Vaccins incluant du nada oligomère de la méningococcie pour une protection élargie contre des lignées hypervirulentes |
| GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
| CA2522379C (fr) | 2003-04-10 | 2012-10-23 | Chiron Corporation | Le coronavirus du syndrome respiratoire aigu grave |
| CA2522238A1 (fr) | 2003-04-15 | 2004-10-28 | Intercell Ag | Antigenes s-pneumoniae |
| DE10327439A1 (de) | 2003-06-18 | 2005-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Imidazopyridazinon- und Imidazopyridonderivate, deren Herstellung und deren Verwendung als Arzneimittel |
| JP4896715B2 (ja) | 2003-06-26 | 2012-03-14 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | Ｃｈｌａｍｙｄｉａｔｒａｃｈｏｍａｔｉｓに対する免疫原性組成物 |
| GB0316560D0 (en) | 2003-07-15 | 2003-08-20 | Chiron Srl | Vesicle filtration |
| ES2505695T3 (es) | 2003-07-31 | 2014-10-10 | Novartis Vaccines And Diagnostics, Inc. | Composiciones inmunógenas para Streptococcus pyogenes |
| US20070134263A1 (en) | 2004-02-18 | 2007-06-14 | Anderson Annaliesa S | Polypeptides for inducing a protective immune response against staphyloococcus aureus |
| GB0419627D0 (en) | 2004-09-03 | 2004-10-06 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
| BRPI0515520A (pt) | 2004-09-22 | 2008-07-29 | Glaxosmithkline Biolog Sa | composição imunogênica, vacina, métodos de preparar uma vacina e de prevenir ou tratar infecção estafilocócica, e, uso de composição imunogênica |
| EP2682126B1 (fr) | 2005-01-27 | 2016-11-23 | Children's Hospital & Research Center at Oakland | Vaccins à vésicule à base de GNA1870 pour protection spectrale élargie contre les maladies causées par Neisseria Meningitidis |
| RU2008130893A (ru) | 2005-12-27 | 2010-02-10 | ОБЕТЕК, ЭлЭлСи (US) | Адипогенные аденовирусы как биомаркеры заболеваний |
| EP2368570A3 (fr) | 2006-01-18 | 2012-05-02 | University Of Chicago | Compositions et procédés liés aux protéines des bactéries staphylocoques |
| EP1994047A2 (fr) | 2006-02-17 | 2008-11-26 | Novartis AG | Purification et utilisation de pili et proteines de pilus de streptococcus pneumoniae |
| ATE539079T1 (de) * | 2006-03-23 | 2012-01-15 | Novartis Ag | Imidazochinoxalinverbindungen als immunmodulatoren |
| AR060188A1 (es) | 2006-03-30 | 2008-05-28 | Glaxosmithkline Biolog Sa | Procedimiento de conjugacion |
| US20100021503A1 (en) | 2006-03-30 | 2010-01-28 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
| WO2009111337A1 (fr) * | 2008-03-03 | 2009-09-11 | Irm Llc | Composés et compositions servant de modulateurs de l’activité des tlr |
| AU2010258677B2 (en) * | 2009-06-10 | 2016-10-06 | Glaxosmithkline Biologicals S.A. | Benzonaphthyridine-containing vaccines |
| CN102760226B (zh) * | 2011-04-29 | 2015-07-01 | 贵州师范大学 | 一种基于实心正方形的试卷客观题答题卡定位方法 |
-
2010
- 2010-08-31 JO JOP/2010/0304A patent/JO3257B1/ar active
- 2010-08-31 TW TW099129346A patent/TWI445708B/zh active
- 2010-09-01 LT LTEP10807754.6T patent/LT2473508T/lt unknown
- 2010-09-01 WO PCT/US2010/047587 patent/WO2011049677A1/fr active Application Filing
- 2010-09-01 ES ES10807754.6T patent/ES2627669T3/es active Active
- 2010-09-01 JP JP2012528021A patent/JP5525614B2/ja active Active
- 2010-09-01 CA CA2772657A patent/CA2772657C/fr active Active
- 2010-09-01 DK DK10807754.6T patent/DK2473508T3/en active
- 2010-09-01 CN CN201080049422.8A patent/CN102712636B/zh active Active
- 2010-09-01 PE PE2012000285A patent/PE20121156A1/es active IP Right Grant
- 2010-09-01 EA EA201200406A patent/EA020962B1/ru not_active IP Right Cessation
- 2010-09-01 PL PL10807754T patent/PL2473508T3/pl unknown
- 2010-09-01 PT PT108077546T patent/PT2473508T/pt unknown
- 2010-09-01 HU HUE10807754A patent/HUE032323T2/en unknown
- 2010-09-01 SI SI201031468A patent/SI2473508T1/sl unknown
- 2010-09-01 BR BR112012004696A patent/BR112012004696B8/pt active IP Right Grant
- 2010-09-01 MX MX2012002654A patent/MX2012002654A/es unknown
- 2010-09-01 US US12/874,153 patent/US9045470B2/en active Active
- 2010-09-01 AU AU2010308524A patent/AU2010308524B2/en active Active
- 2010-09-01 EP EP10807754.6A patent/EP2473508B1/fr active Active
- 2010-09-01 IN IN2736DEN2012 patent/IN2012DN02736A/en unknown
- 2010-09-02 AR ARP100103222A patent/AR078153A1/es active IP Right Grant
- 2010-09-02 UY UY0001032874A patent/UY32874A/es unknown
-
2012
- 2012-02-29 CL CL2012000535A patent/CL2012000535A1/es unknown
-
2015
- 2015-04-24 US US14/696,165 patent/US20150225432A1/en not_active Abandoned
-
2017
- 2017-05-11 HR HRP20170707TT patent/HRP20170707T1/hr unknown
- 2017-06-08 CY CY20171100605T patent/CY1119618T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN02736A (fr) | ||
| SG178954A1 (en) | Immunogenic compositions including tlr activity modulators | |
| JO3065B1 (ar) | مركبات وتركيبات كمعدلات لفاعلية tlr | |
| MX341395B (es) | Compuestos (lipopeptidos basados en cisteina) y composiciones como agonistas de tlr2 usados para el tratamiento de infecciones, inflamaciones, enfermedades respiratorias, etc. | |
| AU2012253757A8 (en) | Partially saturated tricyclic compounds and methods of making and using same | |
| MX344238B (es) | Compuestos de tetrazol y métodos para preparar y usar los mismos. | |
| UA115983C2 (uk) | Інгібітори днк-пк | |
| MX2012013731A (es) | Vacunas que comprenden colesterol y cpg como moleculas portadoras-adyuvantes unicas. | |
| MX343687B (es) | Compuestos sulfonamida tricíclica y métodos para su fabricación y uso. | |
| UA103930C2 (ru) | Соединения и композиция для лечения паразитарных болезней | |
| PH12015501637A1 (en) | Inactivated dengue virus vaccine with aluminium-free adjuvant | |
| MX2012004078A (es) | Compuestos y composiciones como moduladores de la actividad de gpr119. | |
| MX2011013032A (es) | Inhibidores de fosfatidilinositol 3-cinasa. | |
| MX2015005732A (es) | Compuestos tricíclicos y métodos para hacer y utilizar los mismos. | |
| MX2011011618A (es) | Agentes terapeuticos 713. | |
| TN2012000217A1 (en) | The use of an l3 and/or l5 source as a vaccine or as a diagnostic for a parasitic disease | |
| BR112013023354A2 (pt) | vacina para rinite equina | |
| EA201291384A1 (ru) | Терапевтические агенты 976 | |
| TN2010000338A1 (en) | Vaccine comprising a ribosomal protein extract (rpe) and optionally a th1-promoting adjuvant | |
| TN2010000463A1 (en) | Compositions and methods for preparing and using same | |
| MX361456B (es) | Uso de una fuente de l3 y/o l5 como vacuna o como diagnostico para una enfermedad parasitaria. | |
| UA97289C2 (ru) | Соединения и их композиция как модуляторы gpr119 активности |